Categories Earnings, Health Care, LATEST
PetMed (PETS) Q3 earnings drop but beat Street view; sales miss
Earnings of PetMed Express Inc. (NASDAQ: PETS) decreased in the third quarter even as net sales remained unchanged. The bottom line, however, exceeded the market’s expectations.
Net income dropped to $6.8 million or $0.34 per share in the third quarter from $7.7 million or $0.38 per share a year earlier. Earnings, however, exceeded analysts’ forecast. At $59.9 million, net sales were broadly flat year-over-year but below the market’s expectations.
Order Growth
During the three-month period, the average order size edged up to $85 from $84 last year. Reorder sales increased 1% annually to $53.8 million.
The management’s successful efforts to establish direct purchasing relationships with leading manufacturers and the implementation of minimum advertised price policy have translated into margin growth. Total operating expenses decreased 2% to $9.8 million.
Competition
Of late, the company has been focused on marketing and promotional activities as it continues to face stiff competition from rival pet pharmacy Chewy (CHWY). Last month, Chewy reported a net loss for its third quarter, despite an increase in sales. The bottom line was impacted by higher operating expenses.
“In 2020, we will focus on optimizing our marketing in this more competitive environment and being more efficient with our advertising spending. In addition, we will continue investing in our e-commerce platform to better service our customers. This platform will enable us to improve upon our already strong net promoter score of 84.0%.“ said PetMed’s CEO Menderes Akdag.
Dividend
In the third quarter, PetMed’s board of directors declared a quarterly cash dividend of $0.27 per share, which will be paid on February 14, 2020, to shareholders of record on February 3, 2020.
Also read: Retail space gets busy as firms see new opportunities
Last week, PetMed shares climbed to the highest level in twelve months. The stock closed the last trading session notably higher but traded lower during Tuesday’s premarket trading hours. Since the beginning of the year, it gained about 17%.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on